Second shot of smart cells aims to rescue failing hearts
NCT ID NCT07516288
First seen Apr 12, 2026 · Last updated May 23, 2026 · Updated 5 times
Summary
This early-stage trial tests whether a second infusion of a patient's own modified immune cells (CAR-DC) can safely improve heart function in people with end-stage dilated cardiomyopathy. The cells target a protein called FAP to calm harmful inflammation. Only 5 adults who previously received one dose but later worsened will be enrolled. The main goal is to check safety and see if a repeat dose helps the heart pump better.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.